On 21 July, HDN Investment Joint Stock Company, in collaboration with Relisys and Cho Ray Hospital, organized the scientific workshop entitled "Advances in Transcatheter Aortic Valve Implantation (TAVI) Technology." The event marked the first stop of the regional TAVI scientific workshop series in Southern Vietnam, introducing Relisys' latest transcatheter heart valve technologies to healthcare professionals in the region.

Representatives from HDN and Relisys with physicians from the Cardiovascular Center during the scientific workshop.

As one of Vietnam's highest-level tertiary referral hospitals, Cho Ray Hospital was selected as the inaugural venue for the workshop series. The program was designed to provide updates on current developments in transcatheter treatment for aortic valve disease while facilitating scientific exchange among interventional cardiologists and clinicians.

The scientific agenda featured a presentation delivered by a clinical specialist from Relisys, focusing on recent technological advances in transcatheter aortic valve implantation (TAVI), clinical experience, and current trends in structural heart interventions. Following the presentation, participants had the opportunity to review the devices during a hands-on product demonstration and technical discussion.

The Relisys clinical specialist introduces the Vienna Transcatheter Aortic Valve, with participating physicians engaging in technical discussion and product review.

The workshop was attended by physicians from the Cardiovascular Center of Cho Ray Hospital, one of the leading cardiovascular referral centers in Southern Vietnam. Discussions focused on Relisys' self-expanding valve technologies, including the Vienna Transcatheter Aortic Valve and the TricValve Transcatheter Bicaval Valve System, with participants exchanging perspectives on device design, procedural considerations, and potential clinical applications.

Related article: Discover Vienna – A Minimally Invasive Transcatheter Aortic Valve Implantation Solution

The Vienna Transcatheter Aortic Valve was presented as an innovative self-expanding valve technology designed for the treatment of aortic stenosis, with potential applications in clinical practice in Vietnam.

The scientific discussions highlighted the role of minimally invasive transcatheter therapies in the management of patients with aortic valve disease. Participants also exchanged clinical perspectives on device characteristics, procedural techniques, and future developments in structural heart interventions.

As the exclusive distributor of Relisys products in Vietnam, HDN Investment Joint Stock Company sincerely thanks all physicians and healthcare professionals who participated in the workshop. HDN remains committed to collaborating with clinical partners to support scientific education and facilitate access to innovative cardiovascular technologies for healthcare professionals across Vietnam.

Related article: Updates on Transcatheter Heart Valve Technologies at E Hospital